Aurinia (AUPH) Form 4: Director has 2,716 shares withheld

Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director.

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director. On 11/21/2025, a director had 2,716 common shares withheld at a price of $15.68 per share to cover tax obligations when restricted stock units vested. This was recorded as a disposition of shares for tax purposes, not an open-market sale. After this transaction, the director beneficially owns 22,775 common shares, held directly.

The filing clarifies that the reported transaction represents shares withheld to satisfy tax withholding obligations upon RSU vesting, which is a common administrative equity compensation event for insiders.

Insider Trade Summary

Exercise Price or Tax Liability: 2,716 shares

Exercise Price or Tax Liability 1 txn

Insider Bailey Jeffrey Allen

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	2,716	$15.68	$43K

Holdings After Transaction: Common Shares — 22,775 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aurinia Pharmaceuticals (AUPH) report on this Form 4?

The Form 4 reports that a director of Aurinia Pharmaceuticals Inc. (AUPH) had 2,716 common shares withheld on 11/21/2025 to cover tax obligations arising from the vesting of restricted stock units.

Was the Aurinia (AUPH) Form 4 transaction an open-market sale of shares?

No. The explanation states that the 2,716 shares represent shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units, rather than an open-market sale.

How many Aurinia (AUPH) shares does the reporting person own after this Form 4 transaction?

Following the reported tax withholding transaction, the director beneficially owns 22,775 common shares of Aurinia Pharmaceuticals Inc., held in direct ownership form.

What is the relationship of the reporting person to Aurinia Pharmaceuticals (AUPH)?

The filing indicates that the reporting person is a Director of Aurinia Pharmaceuticals Inc., as shown in the relationship section where the Director box is checked.

What was the price used for the withheld Aurinia (AUPH) shares on the Form 4?

The 2,716 common shares withheld to cover tax obligations were reported at a price of $15.68 per share in Table I of the Form 4.

What is the stated reason for the share disposition on this Aurinia (AUPH) Form 4?

The explanation of responses notes that the transaction represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units awarded to the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/24/2025 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey Jeffrey Allen

(Last) (First) (Middle)

#140, 14315-118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/21/2025		F		2,716(1)	D	$15.68	22,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Remarks:

	/s/ Jeffrey A. Bailey	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.